AltheaDx, Inc., a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced that it has raised $27 million in its Series D funding.

The Series D funding will provide operating capital as AltheaDx expands its sales force and scales up marketing efforts following the successful completion of its pivotal double-blinded randomized controlled neuropsychiatric clinical trial for which the company now awaits a local coverage determination from CMS. The Company has also initiated discussions with various partners to expand internationally.

"This financing is an important milestone in the continued commercialization of our IDgenetix offering and the growth of AltheaDx," said Jorge Garces, President and Chief Executive Officer. "We now have strong clinical evidence further demonstrating the clinical utility of our testing in improving patient outcomes with clear health economic benefits and we will continue to work with payors to secure long-term reimbursement. This year will be an exciting and pivotal year for us."

About AltheaDx

AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA. For more information, visit www.altheadx.com.